Further Review of Aspirin in the Treatment of Kawasaki Disease
Asian Journal of Pediatric Research,
Page 13-20
DOI:
10.9734/ajpr/2022/v10i3197
Abstract
Aspirin only prevents platelets from accumulating in the dilated coronary arteries and prevents thrombosis, thus minimizing thrombosis as much as possible, and does not shrink the already dilated coronary artery tumor. Therefore, it plays an important role in the treatment of Kawasaki disease, but it is not the cause of treatment. Aspirin is common in the treatment of Kawasaki disease in children, and its effect is to reduce acute inflammatory response and alleviate platelet aggregation. Aspirin has been used to treat Kawasaki disease for more than 50 years. Since 1961, when Kawasaki discovered the first reported case of hemorrhagic shock caused by aspirin in children with Kawasaki disease, we need to re-explores the use of aspirin in the treatment of Kawasaki disease.
Keywords:
- Aspirin
- Kawasaki disease
- coronary artery damage
How to Cite
Shi, Z., Hsieh, K.-S., Wang, H., Yang, X., Zhang, L., Kong, X., Feng, J., Wang, J., & Jiao, F. (2022). Further Review of Aspirin in the Treatment of Kawasaki Disease. Asian Journal of Pediatric Research, 10(3), 13-20. https://doi.org/10.9734/ajpr/2022/v10i3197
References
Kai-Sheng Hsieh, Ken-Pen Weng, Chu-Chuan Lin, et al. Treatment of acute Kawasaki disease: Aspirin's role in the Febrile Stage Revisited, Pediatrics. 2004; 114 (6):e689-693.
UK-TIA Study Group. The United Kingdom trans ient is chaem ic attack (UK-TIA) aspirin trial:final results(J). J Neurol Neurosurg Psychiatry. 19991;54:1044-1054.
Ren Linlin, Wang Caixia, Li Jing, et al. Chinese medicine combined with gamma globulin and aspirin in the treatment of kawasaki disease (J). Chinese Journal of Modern integrated Traditional and Western Medicine. 2016; 25(17):1890-1892.
He J, Whelton PK, Vu B, et al. Aspirin and risk of hem or rhag ic stroke: a meta-analysis of ran domized controlled trials(J).JA-MA. 1998;280:1930- 1935.
Sehgal S, Chen X, Ang J Y. Epidemiology, Clinical Presentation，and Outcomes of Kawasaki Disease Among Hospitalized Children in an Inner City Hospital Before and After Publication of the American Academy of Pediatrics/American Heart Asso—ciation Guidelines for Treatment of Kawasaki Disease:An 11-Year Period[J]. Clin Pediatr(Phila). 2015;54(13):1283- 1289.
Santklli F, Pignatelli P, Violi F et al. Aspirin for primary pre-venion, in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefi profile to personalised treatment [J]. Thromb Haemost. 2015; 114(5):876—88.
McCrindle BW, Rowley AH, Newburger JW, eta1.Diagnosis, Treatment and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association [J]. Circulation. 2017;135(17): e927-e999.
Ghimire LV, Chou FS, Mahotra NB, et al. Anupdateonthe epidemiology, length of stay and cost of Kawasaki disease hospitalisation in the United States [J]. Cardiol Young. 2019;29(6):828-832.
Kitano N, Takeuehi T, Suenaga T, et al. Seasonal variation in epidemiology of Kawasaki disease related coronary artery abnormalities in Japan. 1999—2017 [J]. J Epidemiol; 2020.
DOI:10.2188/jea.JE20190189.[Epubaheadof print'].
Goni Lee, MD, Seung Eun Lee, MD, Young Mi Hong et al,Is High-Dose Aspirin Necessary in the Acute Phase of Kawasaki Disease? Korean Circ J. 2013;43:182- 186.
Meissner HC, Schliver, Leng DY, et al. Mechanisms of innunoglobuin action: observations on Kawasaki syndrome and RSV prophylaxis. Immunological Reviews. 1994;139:109.
Yichang Liang, Yamei Hu, Zaifang Jiang, Applied Pediatrics, 6th edition. Beijing: People's Medical Publishing House. 1996:688.
Zeng Qing Du, Xiuling Tian. Clinical analysis of kawasaki disease in 140 cases. J Clin Pediatr. 1998;16(5):331-332.
Huang Ming. Clinical analysis of 57 cases of Kawasaki disease. J Clin Pediatr. 1998;16(5):332-333.
Agarwal S, Agrawal DK. Kawasaki disease: Etiopathogenesis and novel trestment strategies (J). Expert Rev Clin Immunol. 2017,13(3):247-258.
Zheng X, Yue P, Liu L, et al. Effivavy between low and high dose aspirin for the initial treatment of Kawasaki disease: Current evidence based on a metaanalysis (J). PloS One. 2019;14(5): e0217274.
Kim GB, Yu JJ, Yoon KI, et al. Medium-or Higher-DOSE Acetyl-salicylic Acid for Acute Kawasaki Disease and Patient Outcomes(J). Int J Rheum Dis. 2018; 184:125-129.
Amalyo G, Koren Y, Brik Simon D, et al. High dose aspirin for Kawasaki disease: outdated myth or effective aid? [J]. Clin Exp Rheumatol. 2017;35Suppl 103(1): 209-212.
Yoo JW,Kim JM,Ki l HR.The outcome of short –term low-dose a spirin treatment in Kawasaki disease based on inflammatory markers[J].Korean J Pediatr. 2017,60(1): 24-29.
Cheng Liping. Clinical study of aspirin enteric-coated tablets in treatment of kawasaki disease (J). Chinese Journal of Clinical Pharmacology. 2017;15(33):43-45.
UK-TIA Study Group. The United Kingdom trans ient is chaem ic attack (UK-TIA) aspirin trial:final results(J). J Neurol Neurosurg Psychiatry. 19991;54:1044-1054.
Ren Linlin, Wang Caixia, Li Jing, et al. Chinese medicine combined with gamma globulin and aspirin in the treatment of kawasaki disease (J). Chinese Journal of Modern integrated Traditional and Western Medicine. 2016; 25(17):1890-1892.
He J, Whelton PK, Vu B, et al. Aspirin and risk of hem or rhag ic stroke: a meta-analysis of ran domized controlled trials(J).JA-MA. 1998;280:1930- 1935.
Sehgal S, Chen X, Ang J Y. Epidemiology, Clinical Presentation，and Outcomes of Kawasaki Disease Among Hospitalized Children in an Inner City Hospital Before and After Publication of the American Academy of Pediatrics/American Heart Asso—ciation Guidelines for Treatment of Kawasaki Disease:An 11-Year Period[J]. Clin Pediatr(Phila). 2015;54(13):1283- 1289.
Santklli F, Pignatelli P, Violi F et al. Aspirin for primary pre-venion, in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefi profile to personalised treatment [J]. Thromb Haemost. 2015; 114(5):876—88.
McCrindle BW, Rowley AH, Newburger JW, eta1.Diagnosis, Treatment and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association [J]. Circulation. 2017;135(17): e927-e999.
Ghimire LV, Chou FS, Mahotra NB, et al. Anupdateonthe epidemiology, length of stay and cost of Kawasaki disease hospitalisation in the United States [J]. Cardiol Young. 2019;29(6):828-832.
Kitano N, Takeuehi T, Suenaga T, et al. Seasonal variation in epidemiology of Kawasaki disease related coronary artery abnormalities in Japan. 1999—2017 [J]. J Epidemiol; 2020.
DOI:10.2188/jea.JE20190189.[Epubaheadof print'].
Goni Lee, MD, Seung Eun Lee, MD, Young Mi Hong et al,Is High-Dose Aspirin Necessary in the Acute Phase of Kawasaki Disease? Korean Circ J. 2013;43:182- 186.
Meissner HC, Schliver, Leng DY, et al. Mechanisms of innunoglobuin action: observations on Kawasaki syndrome and RSV prophylaxis. Immunological Reviews. 1994;139:109.
Yichang Liang, Yamei Hu, Zaifang Jiang, Applied Pediatrics, 6th edition. Beijing: People's Medical Publishing House. 1996:688.
Zeng Qing Du, Xiuling Tian. Clinical analysis of kawasaki disease in 140 cases. J Clin Pediatr. 1998;16(5):331-332.
Huang Ming. Clinical analysis of 57 cases of Kawasaki disease. J Clin Pediatr. 1998;16(5):332-333.
Agarwal S, Agrawal DK. Kawasaki disease: Etiopathogenesis and novel trestment strategies (J). Expert Rev Clin Immunol. 2017,13(3):247-258.
Zheng X, Yue P, Liu L, et al. Effivavy between low and high dose aspirin for the initial treatment of Kawasaki disease: Current evidence based on a metaanalysis (J). PloS One. 2019;14(5): e0217274.
Kim GB, Yu JJ, Yoon KI, et al. Medium-or Higher-DOSE Acetyl-salicylic Acid for Acute Kawasaki Disease and Patient Outcomes(J). Int J Rheum Dis. 2018; 184:125-129.
Amalyo G, Koren Y, Brik Simon D, et al. High dose aspirin for Kawasaki disease: outdated myth or effective aid? [J]. Clin Exp Rheumatol. 2017;35Suppl 103(1): 209-212.
Yoo JW,Kim JM,Ki l HR.The outcome of short –term low-dose a spirin treatment in Kawasaki disease based on inflammatory markers[J].Korean J Pediatr. 2017,60(1): 24-29.
Cheng Liping. Clinical study of aspirin enteric-coated tablets in treatment of kawasaki disease (J). Chinese Journal of Clinical Pharmacology. 2017;15(33):43-45.
-
Abstract View: 106 times
PDF Download: 47 times
Download Statistics
Downloads
Download data is not yet available.
